Elevated Plasma Vascular Endothelial Cell Growth Factor and Thrombomodulin in Juvenile Diabetic Patients

Abstract

The major cause of morbidity and mortality in pa tients with type 1 diabetes mellitus is vascular disease and the death rate in this group of patients can be up to six times that of the general population. Elevated levels of blood glucose can cause endothelial cell damage, and markers of endothelial dam age such as von Willebrand factor (vWF) and thrombomodulin (TM) have been reported to increase in adult diabetic patients. Growth factors are strongly linked to smooth muscle cell pro liferation that contributes significantly to the vascular occlusive process and it has been shown that vascular endothelial cell growth factor (VEGF) stimulates release of vWF from endo thelial cells. Vascular endothelial cell growth factor levels have been shown to be increased in vitreous fluid from the eyes of diabetic patients with proliferative retinopathy compared to those without. In this study we have shown that plasma levels of both TM and VEGF were significantly increased in juvenile diabetic patients with no clinical evidence of vascular disease compared to normal age and sex-matched control subjects. Me dian TM levels were 45.5 ng/mL (I.Q.R. 34 to 56 ng/mL) and 61 ng/mL (I.Q.R. 41 to 72 ng/mL) in the control group and in the diabetic patients respectively (p = .0005) and median lev els of VEGF were 19.6 pg/mL (I.Q.R, 15.9 to 28.1 pg/mL) in the control group and 37.1 pg/mL (I.Q.R. 22.1 to 50.3 pg/mL) in the diabetic patients (p = .027 Mann-Whitney U test). This suggests that microvascular disease begins in childhood and can be detected using laboratory tests before any clinical changes are apparent. Key Words: Diabetes mellitus— Thrombomodulin—Vascular endothelial cell growth factor.

References

Janka HU , Standl E. , Mehnert H. Peripheral vascular disease in diabetes mellitus and its relation to cardiovascular risk factors: screening with the Doppler ultrasound technique. Diabetes Care 1980;207:13.

Deckert T. , Poulsen JE , Larsen M. Prognosis of diabetics with diabetes onset before the age of 31. Diabetologia 1978;14:463.

Lorenzi M. , Cagliero E. , Toledo S. Glucose toxicity for human endothelial cells in culture: delayed replication, disturbed cell cycle and accelerated death. Diabetes 1985;34:621.

Lau CS , McLaren M. , Belch Jjf. Factor VIII von Willebrand factor antigen levels correlate with symptom severity in patients with Raynaud's Phenomenon. Br J Rheumatol 1991;30:433.

Porta M. von Willebrand factor as an indicator of endothelial cell dysfunction in diabetic microangiopathy: studies in vivo. Diabet Med 1988;14:523.

Esmon TC , Owen WG Identification of an endothelial cofactor for thrombin-catalysed activation of protein C. Proc Natl Acad Sci USA 1981;78:2249.

Prowse CV , Farrugia A. , Boulton FE , et al. A comparative study using immunological and biological assays of haemostatic responses to DDAVP infusion, venous occlusion and exercise in normal men. Thromb Haemost 1984;51:110.

Juhan-Vague I. , Conte-Devlox B. , Aillaud MF , et al. Effects of DDAVP and venous occlusion on the release of tissue-type plasminogen activator and von Willebrand factor in patients with panhypopituitarism. Thromb Res 1984;33:653.

Shimano H. , Takahashi K. , Kawakami M. , et al. Elevated serum and urinary thrombomodulin levels in patients with non insulin-dependent diabetes mellitus. Clin Chem Acta 1994;225:89.

10.

Gruden G. , Pagano G. , Romagnoli R. , et al. Thrombomodulin levels in insulin-dependent diabetics with microalbuminuria . Diabet Med 1995; 12:258.

11.

Rinno K. , Kuramoto T. , Iijima T. , et al. Measurement of soluble thrombomodulin in sera from various clinical stages of diabetic neuropathy. J Clin Lab Anal 1996;10:119.

12.

Inukai T. , Fujiwara Y. , Tayama K. , et al. Clinical significance of measurement of urinary and serum thrombomodulin in patients with non insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1996;33:99.

13.

Gabat S. , Keller C. , Kempe HP , et al. Plasma levels of thrombomodulin—a marker for microvascular complications in diabetes mellitus. J Vasc Dis 1996;25:233.

14.

Ferrara N. , Houck K. , Jakeman L. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992;13:18.

15.

Midy V. , Plouet J. Vasculotropin vascular endothelial growth factor induces differentiation in cultured osteoblasts. Biochem Biophys Res Commun 1994;199:380.

16.

Adamis AP , Miller JW , Bernal MT , et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994;118:445.

17.

Murata T. , Ishibashi K. , Khalil A. , et al. Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels. Ophthalmic Res 1995;27:48.

18.

Diabetes Control and Complications Trial Research Group. The effect of intensive insulin treatment of diabetes in the development and progression of long-term complications of insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977.

19.

Wilson SB , Jennings PE , Belch Jjf. Detection of microvascular impairment in type-1 diabetics by laser Doppler flowmetry. Clin Physiol 1992;12:195.

20.

Galajda P. , Martinka E. , Mokan M. , Kubisz P. Endothelial markers in diabetes mellitus. Thromb Res 1997;85:63.

21.

McLaren M. , Jennings PE , Forbes CD , Belch Jjf. Fibrinolytic response to venous occlusion in diabetics with and without microangiopathy compared to age and sex-matched control. Fibrinolysis 1990;4:95.